RHYTHM PHARMACEUTICALS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
NVIDIA's earnings boosted tech stocks, with the Nasdaq up 1.57%. Bitcoin ETFs saw $2.8B inflows, while oil rose 2.17% due to geopolitical concerns. Analysts upgraded Baozun, Element Solutions, and others, while downgrading EHang and Workday.
Rhythm Pharmaceuticals (RYTM) received marketing approval in Japan for its drug IMCIVREE. The stock has gained 11% in the past month and 24% in 90 days. Analysts suggest the company may be 15% undervalued, with a fair value estimate of $134, but it trades at a high P/S ratio of 32.5x.
Analysts upgraded Alphabet (GOOGL) to Buy, Ford (F) to Buy, Rivian (RIVN) to Overweight, and Rocket Lab (RKLB) to Outperform. Downgrades include Stellantis (STLA) to Underweight, Huntington Bancshares (HBAN) to Neutral, and Warner Bros. Discovery (WBD) to Neutral. JPMorgan reiterated a $4,500 year-end gold target. Bitcoin dropped to $65,149 amid risk-off selling. Over 150 S&P 500 companies report earnings this week, including four Magnificent 7 firms.
Over the past 7 days, alphai's AI scored 5 news stories mentioning RYTM (RHYTHM PHARMACEUTICALS, INC.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent RYTM coverage spans financial news, insider activity and regulation.
In the last 30 days, RYTM insiders filed 12 SEC Form 4 transactions — no purchases and 12 sales ($17.0M). The most active reporter was Mazabraud Yann, EVP, Head of International, with 6 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
New coverage with neutral stance.
The approval unlocks a new market, likely boosting revenue and share price.
Overweight initiation may boost interest.
Regulatory clearance opens a new market for IMCIVREE, potentially boosting revenues.
Positive earnings and expanded indication suggest revenue growth potential.
alphai scores every news story that mentions RYTM with an AI model for sentiment and relevance, and aggregates insider trades from RHYTHM PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NVIDIA's earnings boosted tech stocks, with the Nasdaq up 1.57%. Bitcoin ETFs saw $2.8B inflows, while oil rose 2.17% due to geopolitical concerns. Analysts upgraded Baozun, Element Solutions, and others, while downgrading EHang and Workday.
2 min readRhythm Pharmaceuticals (RYTM) received marketing approval in Japan for its drug IMCIVREE. The stock has gained 11% in the past month and 24% in 90 days. Analysts suggest the company may be 15% undervalued, with a fair value estimate of $134, but it trades at a high P/S ratio of 32.5x.
2 min readAnalysts upgraded Alphabet (GOOGL) to Buy, Ford (F) to Buy, Rivian (RIVN) to Overweight, and Rocket Lab (RKLB) to Outperform. Downgrades include Stellantis (STLA) to Underweight, Huntington Bancshares (HBAN) to Neutral, and Warner Bros. Discovery (WBD) to Neutral. JPMorgan reiterated a $4,500 year-end gold target. Bitcoin dropped to $65,149 amid risk-off selling. Over 150 S&P 500 companies report earnings this week, including four Magnificent 7 firms.
3 min readRhythm Pharmaceuticals (RYTM) received Japanese approval for IMCIVREE to treat acquired hypothalamic obesity, a rare condition. The approval follows a Phase 3 trial showing significant BMI reduction. Rhythm estimates 5,000-8,000 people in Japan have this condition. The UK also expanded IMCIVREE's authorization. RYTM stock is up 0.99% to $110 at close, down 0.72% in pre-market.
2 min readRhythm Pharmaceuticals (RYTM) develops drugs for rare obesity forms, like Imcivree for POMC deficiency and hypothalamic obesity. Its market expanded with new approvals, and Q2 revenue grew 47% to $71.3M. Billionaire Stanley Druckenmiller's firm invested. The company aims for more approvals, including for Prader-Willi syndrome, but faces risks like competition and clinical setbacks.
3 min readTD Cowen named Rhythm Pharmaceuticals (RYTM) its top pick, citing strong Q2 results and pipeline progress. Imcivree revenue hit $71.3M, up 19% QoQ and 47% YoY, beating estimates. The company plans to advance RM-718 into a pivotal trial. TD Cowen set a $130 price target and Buy rating.
2 min readRhythm Pharmaceuticals (Nasdaq: RYTM) said it appointed Manher “AJ” Joshi, M.D. as Chief Medical Officer effective Aug. 17. Rhythm said Joshi brings over two decades of leadership across discovery, pivotal trials, and global regulatory work, most recently as Chief Development Officer at Soleno Therapeutics. Rhythm’s lead drug is IMCIVREE (setmelanotide).
2 min readShulman Joseph (Chief Technical Officer) sold 5,079 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $119.75 ($0.61M total) on 2026-08-13 under a Rule 10b5-1 trading plan.
2 min readGarfield Alastair (Chief Scientific Officer) sold 7,763 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at an average of $117.57 ($116.11–$119.17, $0.91M total) across 4 trades on 2026-08-13 under a Rule 10b5-1 trading plan.
2 min readLee Jennifer Kayden (EVP, Head of North America) sold 75,834 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $117.38 ($8.90M total) on 2026-08-13 under a Rule 10b5-1 trading plan.
2 min read
